227,555 Shares in IQVIA Holdings Inc. $IQV Bought by Danica Pension Livsforsikringsaktieselskab

Danica Pension Livsforsikringsaktieselskab purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 227,555 shares of the medical research company’s stock, valued at approximately $43,968,000. Danica Pension Livsforsikringsaktieselskab owned approximately 0.14% of IQVIA at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in IQV. Apella Capital LLC raised its holdings in IQVIA by 5.1% in the first quarter. Apella Capital LLC now owns 1,196 shares of the medical research company’s stock valued at $211,000 after acquiring an additional 58 shares in the last quarter. Quadrant Capital Group LLC grew its holdings in IQVIA by 1.3% during the 4th quarter. Quadrant Capital Group LLC now owns 4,792 shares of the medical research company’s stock worth $1,080,000 after acquiring an additional 60 shares in the last quarter. Private Advisor Group LLC grew its holdings in IQVIA by 1.0% during the 3rd quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock worth $1,163,000 after acquiring an additional 63 shares in the last quarter. Breakwater Capital Group increased its position in shares of IQVIA by 3.2% in the 2nd quarter. Breakwater Capital Group now owns 2,073 shares of the medical research company’s stock valued at $401,000 after purchasing an additional 64 shares during the last quarter. Finally, Keybank National Association OH raised its holdings in shares of IQVIA by 0.7% in the 4th quarter. Keybank National Association OH now owns 9,103 shares of the medical research company’s stock valued at $2,052,000 after purchasing an additional 67 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insider Buying and Selling

In other news, insider Keriann Cherofsky sold 558 shares of the business’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the transaction, the insider owned 2,989 shares of the company’s stock, valued at approximately $732,932.69. The trade was a 15.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Eric Sherbet sold 5,000 shares of the stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total value of $1,245,800.00. Following the sale, the insider directly owned 20,999 shares of the company’s stock, valued at approximately $5,232,110.84. This represents a 19.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 12,913 shares of company stock valued at $3,098,793 in the last quarter. 1.70% of the stock is currently owned by insiders.

IQVIA Stock Down 0.4%

Shares of NYSE IQV opened at $240.25 on Wednesday. The business has a 50-day moving average price of $208.88 and a 200 day moving average price of $186.72. The stock has a market cap of $39.54 billion, a PE ratio of 29.81, a price-to-earnings-growth ratio of 2.01 and a beta of 1.18. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $251.36.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The company had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. During the same period in the previous year, the business posted $2.81 earnings per share. IQVIA’s quarterly revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities research analysts forecast that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA announced that its Board of Directors has authorized a stock buyback plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to buy up to 6.8% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.

Analyst Upgrades and Downgrades

IQV has been the topic of several recent analyst reports. Mizuho increased their target price on IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Morgan Stanley reiterated an “equal weight” rating and issued a $200.00 price objective (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. Weiss Ratings raised IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. JPMorgan Chase & Co. boosted their target price on IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Finally, Royal Bank Of Canada increased their price target on shares of IQVIA from $221.00 to $247.00 and gave the company an “outperform” rating in a research note on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $241.88.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.